The new research was published in Nature Communications, a prestigious peer-reviewed journal (link here). The research was reported by News Medical Life Sciences. According to the report, the new discovery is “an initial step towards developing a fully human antibody to treat or prevent the respiratory disease COVID-19 caused by the novel coronavirus SARS-CoV-2.”
Researchers at Utrecht University, Erasmus Medical Center and Harbour BioMed (HBM) today reported that they have identified a fully human monoclonal antibody that prevents the SARS-CoV-2 (COVID-19) virus from infecting cultured cells.
The discovery, published online today in Nature Communications, is an initial step towards developing a fully human antibody to treat or prevent the respiratory disease COVID-19 caused by the novel coronavirus SARS-CoV-2.
Dr. Berend-Jan Bosch of Utrecht University is the Research Leader and Study Co-Lead Author.
[…]Dr. Bosch noted that the antibody binds to a domain that is conserved in both SARS-CoV and SARS-CoV-2, explaining its ability to neutralize both viruses.
“This cross-neutralizing feature of the antibody is very interesting and suggests it may have potential in mitigation of diseases caused by future-emerging related coronaviruses.”
“This discovery provides a strong foundation for additional research to characterize this antibody and begin development as a potential COVID-19 treatment,” said Frank Grosveld, PhD. co-lead author on the study, Academy Professor of Cell Biology, Erasmus Medical Center, Rotterdam and Founding Chief Scientific Officer at Harbour BioMed.
“The antibody used in this work is ‘fully human,’ allowing development to proceed more rapidly and reducing the potential for immune-related side effects.” Conventional therapeutic antibodies are first developed in other species and then must undergo additional work to ‘humanize’ them.
What will be interesting is to see how Facebook, Twitter, YouTube etc. handle this emerging research. I’ve heard that YouTube is suppressing and censoring research that disagrees with the Democrat lockdown narrative. This is because the lockdown is the only chance their candidate Joe Biden has to win in November.
We’ve seen that Democrat feminists are willing to look the other way to excuse rape when their candidate is accused of rape. But will they look the other way from peer-reviewed research in order to extend the economic devastation that is their only chance to win? And will they censor people who publicize actual published research in order to keep people in fear?
I found two new studies that reduce the threat of the Chinese Covid-19 virus. The first one was reported by Sky News, and it’s about a study that says that coronavirus patients cannot contract the disease after they’ve had it once already. And the second study was reported by the Sydney Morning Herald, and it says that the virus cannot be transmitted from children to adults.
No child has been found to have passed coronavirus to an adult, a review of the evidence in partnership with the Royal College of Paediatrics has found.
Major studies into the impact of COVID-19 on young children suggest they “do not play a significant role” in spreading the virus and are less likely to become infected than adults.
While experts insist that more evidence is needed, they note there has not been a single case of a child under 10 transmitting the virus, even in contact tracing carried out by the World Health Organisation (WHO).
Public health officials in Switzerland have announced that under-10s can hug their grandparents again because they pose them no risk.
Now a review in partnership with the Royal College of Paediatrics and Child Health (RCPCH) has found the evidence “consistently demonstrates reduced infection and infectivity of children in the transmission chain”.
Led by Dr Alasdair Munro, a clinical research fellow in paediatric infectious diseases, the research concluded: “COVID-19 appears to affect children less often, and with less severity, including frequent asymptomatic or subclinical infection. There is evidence of critical illness, but it is rare.
“The role of children in transmission is unclear, but it seems likely they do not play a significant role.”
This study just seems like all good news to me. It means that we can be more confident than we were before about re-opening schools.
Anyway, check out the articles and see what you think.
I’m an investor, and I mostly think that the virus is not an issue right now. My biggest concern right now is that we are doing damage to the economy by staying in lockdown. Damage that will really hurt us in the long run because of inflation and massive debt.
An international poll of more than 6,000 doctors finds that the antimalarial drug hydroxychloroquine has been deemed the most highly rated treatment for the novel coronavirus.
The survey, conducted by Sermo, a global health care polling company, asked 6,227 physicians in 30 countries to find out what is the most effective against SARS-CoV-2. The poll finds that 37% of those treating patients suffering from the coronavirus that causes COVID-19 rated hydroxychloroquine as the “most effective therapy” out of a list of 15 choices.
On Monday, the U.S. Food and Drug Administration gave chloroquine and its derivative, hydroxychloroquine, emergency-use authorization, although many physicians were already using the drug.
Azithromycin, known by the brand name Zithromax or Z-Pak, came in as the second-most effective therapy at 32%, followed by “nothing.”
The study I looked at from Science Direct said that the best results are obtained by using a combination of hydroxychloroquine and azithromycin, which is (I think) what Trump had recommended earlier. In fact here’s an example story about a doctor who is using the combination of the two drugs:
An infectious disease doctor told Fox News on Wednesday night that using hydroxychloroquine and azithromycin to treat patients that have the coronavirus was an “absolute game changer” and that it was “the beginning of the end of the pandemic.”
The model used by the White House to calculate infection and death rates is being revised downward – twice.
An influential prediction model, referenced routinely by White House coronavirus task for leader Dr. Deborah Birx, has been updated to reflect a major change in death and bed shortage projections, according to the Associated Press.
The Institute for Health Metrics and Evaluation University of Washington’s School of Medicine now says they’re COVID-19 projection model shows a sharp decline in anticipated deaths, anticipated bed shortages, and even anticipated infections — a change made as new data about the virus’ real-world spread becomes available and analysts are able to monitor epicenters, like New York City, in real time.
A model heavily relied upon by the White House task force responding to the China-originated novel coronavirus, or COVID-19, has again been updated.
On Sunday night, a model from the Institute of Health Metrics and Evaluation (IHME) at the University of Washington dropped its estimated death projection for the first wave of the pandemic to 81,766 deaths, down from 93,531.
“The 11,765 fewer deaths would mark a 14% decrease for the model’s target projection, and a 30% decrease for the worst-case scenario,” The Daily Caller noted Monday.
Some countries are starting to scale back their quarantining and social distancing:
On Monday, Austria became the first European country to announce its plan to begin easing “lockdown” measures amid signs that it has made it through the worst stages of the initial wave of the coronavirus pandemic. Other European countries are reportedly beginning to look with hope toward taking similar steps.
Austria has experienced “three consecutive days in which the number of coronavirus recoveries have exceeded the number of new cases,” The Washington Post explains. “On Monday, Austrian authorities reported 241 new infections over previous 24 hours, but 465 recoveries.”
Things are going so well, that even the Democrats have taken notice.
As many as 4,000 people in New York are currently being treated with hydroxychloroquine, the New York Post reports:
A state Health Department official said the [Department of Health] has shipped doses of hydroxychloroquine to 56 hospitals across New York, distributing enough “to treat 4,000 patients to date.” Patients have received doses as part of four- or 10-day regimens, officials said. The University of Albany’s School of Public Health is observing the drug’s impact on the patients, and its preliminary study could come back in weeks instead of the usual months, officials said.
Cuomo has been criticized for prohibiting pharmacists from dispensing hydroxychloroquine outside a hospital.
New York Gov. Andrew Cuomo (D) said Monday that the number of daily coronavirus deaths in his state has been “effectively flat for two days,” which he said may signal the pandemic is beginning to wane.
New York had 599 new deaths, up from 594 on Sunday but down from 630 on Saturday.
“While none of this is good news, the possible flattening of the curve is better than the increases that we have seen,” Cuomo said.
The governor also said the number of hospitalizations and intensive care admissions have also hit their lowest points in more than two weeks.
A Michigan state Democratic lawmaker who was suffering from the coronavirus credited President Donald Trump with saving her life, saying on Monday that his constant touting of hydroxychloroquine is what led her to ask her doctor for the malaria drug.
Rep. Karen Whitsett (Detroit) “said she started taking hydroxychloroquine on March 31, prescribed by her doctor, after both she and her husband sought treatment for a range of symptoms on March 18,” The Detroit Free Press reported. “‘It was less than two hours’ before she started to feel relief, said Whitsett, who had experienced shortness of breath, swollen lymph nodes, and what felt like a sinus infection.”
[O]n Jan. 31, the president declared coronavirus a U.S. public health emergency and issued a travel ban between the United States and China. Campaigning in Iowa that day, Biden criticized Trump’s China travel ban, saying, “This is no time for Donald Trump’s record of hysteria and xenophobia.”
On Feb. 1, Biden again criticized Trump for the move.
[…]Presumed Democratic presidential nominee Joe Biden now backs restrictions on travel from China — two months after President Donald Trump put them into place to stem the spread of the coronavirus, which originated in Wuhan, China.
It took a few months, but the Democrats and their mainstream media allies are starting to credit Trump for taking the Wuhan virus seriously early on.
And of course the stock market was up 7.5% on Monday. I hope you bought the dip in March. I was out of the market since last summer when the markets crossed over the 52-week highs. I just got back in last month. So far, I’m up 10% in my portfolio, and my nerves are steady. It’s a risk I’m willing to take because the reward is worth it.
There’s been a lot of good news last week, and I tweeted some of it. A lot of private sector companies are stepping up to manufacture the tools needed to defeat the Chinese Wuhan virus. They’re making hand sanitizer, respirator masks, ventilators, and even prescription drugs for testing and treatment. One company really stood out to me, though, so let’s read about them first.
Novartis Chief Executive Vas Narasimhan said Sunday that the Trump-touted drudged hydroxychloroquine, often used to treat malaria, is our biggest hope in combating the China-originated coronavirus, or COVID-19.
Narasimhan pledged to donate a stunning 130 million doses of hydroxychloroquine and will support studies of the drug as a treatment against COVID-19.
Novartis Chief Executive Vas Narasimhan said his Sandoz generics unit’s malaria, lupus and arthritis drug hydroxychloroquine is the company’s biggest hope against the coronavirus, Swiss newspaper SonntagsZeitung reported on Sunday.
Novartis has pledged to donate 130 million doses and is supporting clinical trials needed before the medicine, which U.S. President Donald Trump also has been promoting, can be approved for use against the coronavirus.
“Pre-clinical studies in animals as well as the first data from clinical studies show that hydroxychloroquine kills the coronavirus,” Narasimhan told Swiss newspaper SonntagsZeitung. “We’re working with Swiss hospitals on possible treatment protocols for the clinical use of the drug, but it’s too early to say anything definitively.”
According to Reuters, pharmaceutical companies Bayer and Teva “have also agreed to donate hydroxychloroquine or similar drugs, while Gilead Sciences is testing its experimental drug remdesivir against coronavirus.”
As noted by The Daily Wire on Sunday, France officially sanctioned this weekend chloroquine for certain patients infected with COVID-19.
“The French government has officially sanctioned prescriptions of chloroquine to treat certain coronavirus patients,” France 24 English reported Saturday.
“This ensures continued treatment of patients who have been treated for several years for a chronic condition with this drug, but also allows a temporary authorization to allow certain patients with coronavirus to benefit from this therapeutic route,” said Jérôme Salomon, France’s director general of health.
According to a report from Trustnodes, France’s move comes after infectious disease specialist Didier Raoult announced new clinical results… that show 78 out of 80 patients treated with chloroquine recovered within five days.
Trump is trying to get the FDA to move quickly through testing so that these drugs can be made widely available.
The Daily Wire reported on Sunday night that the FDA is doing everything they can to get these drugs available:
On Sunday night, the Food and Drug Administration (FDA) issued an emergency use authorization for hydroxychloroquine and chloroquine, drugs often used to treat malaria and recently touted by President Donald Trump as a possible “game-changer” in the fight against the China-originated novel coronavirus, or COVID-19.
The United States Department of Health & Human Services (HHS) announced in a statement on Sunday that the FDA will allow the drugs to be “donated to the Strategic National Stockpile to be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible,” a Politico report said.
The statement noted that “Sandoz donated 30 million doses of hydroxychloroquine to the stockpile and Bayer donated 1 million doses of chloroquine.”
Trump made it clear weeks ago that his administration would work to fast-track promising drugs like hydroxychloroquine with the FDA, all in an effort to combat COVID-19.
The drugs are already being tested in New York state:
Democratic New York Governor Andrew Cuomo is on the same page as President Trump when it comes to the popular anti-malaria drugs, permitting trials of hydroxychloroquine, chloroquine, and azithromycin to commence in his state.
“Let’s see how it works,” Trump said Sunday, with regard to the New York trials. “It may. It may not.”
But wait! There’s more good news.
I’m currently tracking 5 different drugs to see how they perform during tests, but here is a sixth one that I didn’t even know about.
Abbott on Friday announced it received approval for a test that is capable of delivering positive results of the coronavirus in as little as five minutes, and it will begin making those tests available to health care providers next week.
The Food and Drug Administration issued emergency use authorization for the point-of-care test on Friday, the company said in a statement. The test can detect negative results in 13 minutes. The company said it plans to ramp up manufacturing so it can deliver 50,000 tests per day.
Scientists studying the coronavirus have some good news: as it is transmitted through the human population, it is not undergoing significant mutations, meaning it will not become more dangerous as it spreads, and once a vaccine is developed, it could be as effective as vaccines for measles or chickenpox are. Peter Thielen, a molecular geneticist at the Johns Hopkins University Applied Physics Laboratory who is one of the scientists examining the virus, told The Washington Post,, “I would expect a vaccine for coronavirus would have a similar profile to those vaccines. It’s great news.”
So, the Trump administration is actually doing a pretty good job of cutting red tape to get people help faster. But a lot of the actual work is being down by private sector companies who are making donations and developing tests and drugs to solve the problem. Just keep that in mind when you here doom and gloom from fake news journalists and Democrat politicians.